Industry sees very little harmony in the way European countries respond to reports of adverse incidents
This article was originally published in Clinica
Companies marketing medical devices in Europe face a bewildering variety of responses from regulatory authorities when they report adverse incidents or near adverse incidents with their products as required by law. Amanda Maxwell reports from a workshop in London which highlighted the differences.
You may also be interested in...
Becton Dickinson will spend $1.2bn over the next four years to improve its drug-delivery device manufacturing capabilities. See what Eric Borin, president of BD, said about it here.
Pfizer is producing vaccine doses at scale now that it has buttoned down the manufacturing process.
In second letter this year targeting email communications, OPDP says that putting the methotrexate oral solution’s risk information below the signature block does not offer ‘prominence and readability’ comparable to the information on the drug’s effectiveness for the treatment of acute lymphoblastic leukemia that was in the body of the email.